Please login to the form below

regorafenib

This page shows the latest regorafenib news and features for those working in and with pharma, biotech and healthcare.

Home-grown colorectal cancer drug approved in China

Elunate will have to go up against well-established oral drugs like Bayer’s multikinase inhibitor Stivarga (regorafenib) and Taiho Oncology’s Lonsurf (trifluridine/tipiracil) in the third-line setting.

Latest news

Another IO knockback as Tecentriq combo fails phase III trial

cancer (CRC) showed no benefit on overall survival compared to Bayer’s Stivarga (regorafenib), a drug typically used in that hard-to-treat population. ... The results from IMblaze370 were consistent with this prior monotherapy experience, showing that
NICE backs Pfizer’s Xeljanz for RA

Meanwhile, NICE has decided to remove Bayer ’s gastrointestinal stomach tumour (GIST) treatment Stivarga (regorafenib) from the cancer drugs fund (CDF) to make it routinely available to some patients on the
Bayer's Nexavar backed by NICE for liver cancer

Amanda Cunnington, head of patient access at Bayer UK, said the company recently submitted its new HCC drug Stivarga (regorafenib) for review by NICE and the Scottish Medicines Consortium (SMC) "with
EMA clears Bayer's Stivarga for liver cancer

The European Medicines Agency (EMA) approved oral multikinase inhibitor Stivarga (regorafenib) for patients with HCC who have been treated first-line with Bayer's older drug Nexavar (sorafenib), matching the
FDA OK for Stivarga ends decade-long drought in liver cancer

Oral multikinase inhibitor Stivarga (regorafenib) has been cleared by the US regulator for patients with hepatocellular carcinoma (HCC) who have been previously treated with Bayer's older drug Nexavar (sorafenib).

More from news
Approximately 8 fully matching, plus 37 partially matching documents found.

Latest Intelligence

Pharma deals during August 2013

To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Bayer’s former oncology head Robert Rosen joins AP Pharma

Rosen also led premarket activities for Stivarga (regorafenib) in its indications for gastrointestinal stromal tumours and colon cancer, as well as for alpharadin in prostate cancer.
Former Bayer oncology head Robert Rosen joins AP Pharma's board

He was also involved in pre-market activities for regorafenib in the treatment of patients with gastrointestinal stromal tumours and colon cancer, as well as alpharadin for prostate cancer.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Medical Writer - Creative and Scientific Projects: DOE

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Systematic Review Lead- London: Negotiable

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Medical Writers Required - Hertfordshire: Competitive

Associate Scientific Director: Salary TBC

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior Medical Writer: Salary is DOE

Market Access Consultant - Greater Manchester: Negotiable

Sudler London - Account Director: Competitive

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Healthcare PR Director: £100, 000 – £120, 000 benefits

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Senior Training Manager - Surrey: Competitive Salary &Bonus

Senior Medical Writer, MedComms Agency: Salary TBC

Senior Account Manager – Healthcare Advertising: Salary TBC

Account Manager: Negotiable

Account Manager- 4 days per week or full-time: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....